Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir.
about
Highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: analysis of cellular immune responsesT-helper-cell proliferative responses to whole-killed human immunodeficiency virus type 1 (HIV-1) and p24 antigens of different clades in HIV-1-infected subjects vaccinated with HIV-1 immunogen (Remune)Immune reconstitution in HIV-1 infected subjects treated with potent antiretroviral therapy.Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients.Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapy.Preservation of lymphocyte immunophenotype and proliferative responses in cryopreserved peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected donors: implications for multicenter clinical trials. The ACTG Immunology AdCD4+ T-cell help enhances NK cell function following therapeutic HIV-1 vaccination.Immune therapy: non-highly active antiretroviral therapy management of human immunodeficiency virus-infected patients.Highly active antiretroviral therapy in patients infected with human immunodeficiency virus increases CD40 ligand expression and IL-12 production in cells ex vivo.Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection.Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks.Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170).HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failedIntracellular HIV-Tat expression induces IL-10 synthesis by the CREB-1 transcription factor through Ser133 phosphorylation and its regulation by the ERK1/2 MAPK in human monocytic cells.Reconstitution of human thymic implants is limited by human immunodeficiency virus breakthrough during antiretroviral therapy.Discordance between frequency of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-producing CD4(+) T cells and HIV-1-specific lymphoproliferation in HIV-1-infected subjects with active viral replication.Characteristics of hepatitis C virus infection in HIV-infected people.Effects of NO-Hybridization on the Immunomodulatory Properties of the HIV Protease Inhibitors Lopinavir and Ritonavir.HIV-1 Nef inhibits lipopolysaccharide-induced IL-12p40 expression by inhibiting JNK-activated NFkappaB in human monocytic cells.Immunomodulation in female B₆C₃F₁ mice following treatment with the HIV protease inhibitor saquinavir for 28 days by gavage.Saquinavir up-regulates telomerase activity in lymphocytes activated with monoclonal antibodies against CD3/CD28.Comparative CD4 T-cell responses of reverse transcriptase inhibitor therapy with or without nelfinavir matched for viral exposure.Effects of subcutaneous interleukin-2 therapy on phenotype and function of peripheral blood mononuclear cells in human immunodeficiency virus infected patients.Adrenaline-induced mobilization of T cells in HIV-infected patients.HIV protease inhibitors differentially inhibit adhesion of Candida albicans to acrylic surfaces.Low interleukin-10 production is associated with diabetes in HIV-infected patients undergoing antiviral therapy.Molecular correlates in AIDS patients following antiretroviral therapy: diversified T-cell receptor repertoires and in vivo control of cytomegalovirus replication.Immunomodulants for the treatment of HIV infection: the search goes onAn Immunological Comparison of Third Companion in Advanced Drug-Naive HIV-Infected Patients
P2860
Q28347291-14131DA0-6069-485F-8D5F-D75D64806F86Q30327166-0B70F101-9999-4842-B9D1-6303FEE210B0Q33806165-AB6CB416-8E42-4BBB-BC89-3D0D013AFA51Q33945359-469ACC99-C4C7-465D-A391-889D9FE76111Q33982056-385ADFB6-B065-4B00-95BD-925402D6D769Q33998310-B4C5772F-5F7C-4EFD-876E-3F024220A77EQ34057778-33B324D5-63BA-47AC-94FE-224444B9805CQ34631665-7770B917-DE78-4371-AF60-ED1EAE5B8756Q35158952-8053B13E-88E4-4BDA-A3BF-C19AF3680012Q35920633-F0441445-9333-457E-AEF0-CFCEABC4D43AQ36250357-22C8E672-7EC2-4DE2-857C-8CABBB148E96Q36421569-7F1680C8-3BA3-4FA1-9FC2-A34D71E935EBQ37021823-DC6F8353-AC61-414A-AE4D-C4947D0900E4Q38310502-57217E20-968C-44AD-9E1B-117FCCE21B1CQ39595155-825E385B-8BBC-45BA-B72E-B619BBBD01E8Q39683633-E7D74D99-0703-4578-91F4-0FACFB3A341DQ40663778-7DDD9736-5EB7-4D59-81B6-B924E58DA079Q41026728-A55B8253-733C-4B23-BBCE-01722F6F8601Q42084744-5BE9CA7B-2D47-4834-A32E-099E035904E8Q43013087-F6BB0F20-014F-4368-9BDB-0CD176112D83Q43758470-B64FAA7D-43C6-4C32-B359-CB745CEB2A4FQ43759291-2167C4ED-60FE-4B0B-A91C-22B98EE7431AQ44571925-1825339F-6715-498F-B99B-F395865C05C1Q44784182-EB3C7F31-7882-42F6-B2FF-A439D8E637F4Q45963116-AAC5321E-13A8-4FED-9CB8-69A66EE62285Q46911895-35DD4EA2-D6F5-4F00-A078-2162446A815AQ52016008-4D9AD5CC-40C9-418D-8800-AB7C12EA357AQ57997498-466E644D-1672-4AC9-99E8-E59427192082Q57997508-C6466A0C-74A9-400C-9423-14D3DA94A101
P2860
Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Improvement in cell-mediated i ...... ith ritonavir plus saquinavir.
@en
Improvement in cell-mediated i ...... ith ritonavir plus saquinavir.
@nl
type
label
Improvement in cell-mediated i ...... ith ritonavir plus saquinavir.
@en
Improvement in cell-mediated i ...... ith ritonavir plus saquinavir.
@nl
prefLabel
Improvement in cell-mediated i ...... ith ritonavir plus saquinavir.
@en
Improvement in cell-mediated i ...... ith ritonavir plus saquinavir.
@nl
P2093
P356
P1476
Improvement in cell-mediated i ...... ith ritonavir plus saquinavir.
@en
P2093
Cameron DW
Daftarian P
Diaz-Mitoma F
Leonard JM
P304
P356
10.1086/515244
P407
P577
1998-04-01T00:00:00Z